ATP/ADP Probes Development Service
ATP/ADP balance is a central indicator of cellular energy charge, mitochondrial oxidative phosphorylation, glycolytic adaptation, metabolic stress, drug response, and cell viability. MitoGlowing™ provides a comprehensive ATP/ADP Probes Development Service to support custom fluorescent, luminescent, genetically encoded, and microplate-compatible probe development for ATP/ADP ratio imaging, ADP-selective detection, mitochondrial energy metabolism analysis, cancer metabolism studies, nephrotoxicity evaluation, organoid models, and high-throughput drug screening.
Introduction to ATP/ADP Probes
Adenosine triphosphate (ATP) is the major energy currency of cells, while adenosine diphosphate (ADP) reflects ATP consumption through ATPases, kinases, ion pumps, biosynthesis, cell migration, signaling, and stress responses. The ATP/ADP ratio is therefore a sensitive readout of cellular energetic status. Changes in this ratio can indicate mitochondrial respiratory chain dysfunction, glycolysis dependence, hypoxia, nutrient stress, apoptosis, drug-induced toxicity, or metabolic adaptation in disease models.
For mitochondrial studies, ATP/ADP probe development is especially important because mitochondria continuously regenerate ATP from ADP through oxidative phosphorylation. When electron transport chain activity, substrate supply, membrane potential, or ATP synthase function is perturbed, ATP/ADP dynamics can change rapidly.
ATP/ADP probe development may involve ratiometric fluorescent biosensors, ADP-selective lanthanide luminescent probes, ATP-responsive genetically encoded sensors, bioluminescent ATP/ADP assays, enzymatic cycling workflows, organelle-targeted imaging probes, or high-content screening-compatible reporter systems. Depending on project goals, probes and assays can be optimized for live-cell imaging, organoid models, mitochondrial localization, microplate screening, time-resolved luminescence, drug toxicity evaluation, or integrated metabolic profiling with NADH/NAD⁺, ROS, membrane potential, calcium, oxygen consumption, and cell viability assays.
Fig.1 Schematic diagram of the PercevalHR ATP:ADP ratiometric biosensor, consisting of the ATP-binding protein GlnK1 (magenta) fused to cpmVenus (green).
Features of ATP/ADP Probes Development
- ATP/ADP ratio-responsive probe design through ratiometric fluorescent, genetically encoded, luminescent, bioluminescent, or enzymatic cycling-based systems for monitoring cellular energy status.
- ADP-selective luminescent probe engineering including lanthanide-based or time-resolved luminescent systems that reduce background interference and improve detection selectivity.
- Mitochondria-focused energy metabolism analysis for mitochondrial ATP production, ADP accumulation, oxidative phosphorylation stress, respiratory chain inhibition, ATP synthase dysfunction, and metabolic reprogramming studies.
- Live-cell and real-time imaging compatibility for fluorescence microscopy, confocal imaging, two-photon imaging, high-content imaging, organoid imaging, and selected intravital or preclinical imaging workflows.
- High-throughput screening adaptability for 96-well, 384-well, automated imaging, plate-reader, luminescence-reader, and drug-screening workflows.
- Application-specific biological validation in cancer metabolism models, mitochondrial disease models, nephrotoxicity systems, organoids, oxidative stress models, metabolic inhibitor screening, and drug safety evaluation.
Our Services
MitoGlowing™ provides an integrated ATP/ADP probe development workflow covering probe strategy design, molecular or biosensor engineering, photophysical characterization, biochemical validation, biological testing, and application-specific assay optimization.
Project Design & Energy Readout Strategy
- Define the target application, such as mitochondrial metabolism analysis, ATP/ADP ratio imaging, ADP-selective detection, drug toxicity evaluation, cancer metabolism research, organoid models, or high-throughput screening.
- Select the preferred detection format, including fluorescent probe, luminescent probe, genetically encoded biosensor, bioluminescent assay, enzymatic cycling assay, microplate assay, or high-content imaging workflow.
- Determine key performance requirements, including ATP/ADP specificity, response time, dynamic range, emission wavelength, subcellular localization, assay window, photostability, cytotoxicity, and throughput.
- Design validation strategies using metabolic inhibitors, ATP synthase modulators, glycolysis inhibitors, oxidative phosphorylation inhibitors, ADP/ATP standards, nutrient stress models, and recovery controls.
Molecular Probe & Biosensor Development
- Design ATP- or ADP-responsive probes based on lanthanide complexes, rhodamine, fluorescein, coumarin, BODIPY, cyanine, quinoline, naphthalimide, AIEgen, or other fluorophore scaffolds.
- Develop genetically encoded ATP/ADP biosensor workflows based on PercevalHR-like or customized reporter systems.
- Introduce mitochondrial targeting groups, solubility-enhancing modules, ratiometric signal units, time-resolved luminescent elements, or organelle-compatible localization strategies.
- Optimize water compatibility, response kinetics, signal-to-background ratio, dynamic range, cellular uptake, biosensor expression, and biological compatibility.
- Support assay format development for live cells, cell lysates, organoids, tissue models, drug-treated samples, or screening plates.
Photophysical & Biochemical Characterization
- Measure absorption spectra, emission spectra, excitation/emission maxima, Stokes shift, fluorescence intensity, luminescence lifetime, quantum yield, and spectral separation.
- Evaluate response toward ATP, ADP, AMP, phosphate, pyrophosphate, citrate, NADH, NAD⁺, NADPH, NADP⁺, and related biological anions or cofactors.
- Assess response kinetics, linear detection range, detection limit, selectivity, reversibility, signal stability, and assay reproducibility.
- Test photostability, pH stability, buffer compatibility, serum tolerance, solvent tolerance, protein interference, and storage stability.
- Characterize time-resolved luminescence, two-photon compatibility, microplate compatibility, or high-content imaging suitability when required.
Biological Validation & Imaging Assay Development
- Validate cell permeability, intracellular retention, mitochondrial localization, lysosomal or cytosolic distribution, and co-localization with organelle markers when required.
- Optimize staining concentration, biosensor transfection or stable expression, incubation time, imaging settings, plate format, and signal acquisition parameters.
- Test probe response in metabolic perturbation models, including ATP synthase inhibition, glycolysis inhibition, mitochondrial uncoupling, hypoxia/reoxygenation, nutrient deprivation, and drug-induced energy stress.
- Develop workflows for fluorescence microscopy, confocal imaging, two-photon microscopy, luminescence readers, plate readers, flow cytometry, high-content imaging, organoid imaging, and selected animal model platforms.
- Establish quantitative analysis methods, including fluorescence ratio calculation, luminescence intensity analysis, standard curve generation, ATP/ADP ratio calculation, dose-response curves, IC₅₀ determination, and time-course monitoring.
Supported Sample Types and Models
- Cancer cell lines, tumor spheroids, organoids, and cancer metabolism models
- Mitochondrial dysfunction and oxidative phosphorylation stress models
- Metabolic inhibitor-treated, nutrient-stressed, hypoxia/reoxygenation-treated, or drug-treated cells
- Kidney organoids, renal proximal tubular models, and nephrotoxicity models
- Cardiomyocyte and cardiotoxicity models, including H9C2 cells, primary cardiomyocytes, and iPSC-derived cardiomyocytes
- Neuronal and neurodegenerative disease models, including PC12 cells, SH-SY5Y cells, primary neurons, and brain tissue models
- Ovarian cancer, breast cancer, lung cancer, liver cancer, colorectal cancer, glioma, and melanoma models
- 2D monolayer cultures, 3D organoids, patient-derived organoids, and tissue sections
- Cell lysates, tissue extracts, isolated mitochondria, and selected biological fluids
- 96-well, 384-well, automated imaging, and high-content screening formats
Application
ADP-Selective Luminescent Probe Development for Energy Metabolism Monitoring
Selective ADP detection is challenging because ADP is structurally similar to ATP, AMP, pyrophosphate, and other biological anions. Lanthanide-based ADP probes, such as [Eu.ADPGlow]⁻, demonstrate how time-resolved emission, low background, and ADP-selective binding can support energy metabolism monitoring even under ATP-rich biological conditions.
This application supports ADP-selective probe development for mitochondrial energy stress monitoring, ATPase and kinase activity studies, cancer metabolism research, metabolic inhibitor evaluation, and high-throughput compound screening.
Genetically Encoded ATP/ADP Ratio Biosensors for Drug Screening
Genetically encoded ATP/ADP biosensors enable real-time monitoring of energy metabolism in living cells. PercevalHR-like systems can convert ATP/ADP changes into ratiometric fluorescence signals, while tools that manipulate ATP/ADP balance can create controlled energy stress models for drug-response analysis.
This application supports ATP/ADP biosensor development for tumor drug screening, mitochondrial-targeted compound evaluation, metabolic stress induction, drug safety testing, and early-stage metabolic phenotyping.
ATP/ADP Biosensor Organoids for Drug Nephrotoxicity Assessment
ATP/ADP biosensor organoids can provide real-time energy metabolism readouts in complex 3D tissue-like systems. Kidney organoid models that express ATP/ADP reporters can be used to evaluate drug-induced proximal tubular injury, renal transporter function, and early metabolic stress before irreversible damage occurs.
This application supports ATP/ADP probe development for nephrotoxicity screening, organoid-based drug safety evaluation, renal transporter validation, early tubular injury detection, and 3R-aligned preclinical testing.
Ovarian Cancer Metabolism and Chemotherapy Response Research
ATP/ADP biosensors can be combined with other genetically encoded metabolic reporters to study tumor metabolism across 2D, 3D, and in vivo-related models. Perceval-based ATP/ADP readouts can help assess oxidative stress, metabolic adaptation, and chemotherapy response in ovarian cancer and other solid tumor systems.
This application supports ATP/ADP probe development for solid tumor energy metabolism studies, chemotherapy sensitivity evaluation, 3D organoid metabolic profiling, tumor microenvironment modeling, and metabolism-based therapeutic stratification.
Technology Comparison Summary
| Application Area | Representative Probe / Strategy | Core Value | Development Focus |
|---|---|---|---|
| ADP-selective detection | [Eu.ADPGlow]⁻ and lanthanide luminescent probes | Selective ADP detection under ATP-rich biological conditions | Time-resolved luminescence, low background, ADP selectivity |
| Live-cell ATP/ADP imaging | PercevalHR-like genetically encoded biosensors | Real-time ATP/ADP ratio monitoring in living cells | Ratiometric imaging, biosensor expression, pH correction |
| Drug screening | ATP/ADP biosensors and luminescent microplate assays | Metabolic stress and compound response evaluation | Throughput, assay window, IC₅₀ curves, reproducibility |
| Nephrotoxicity testing | ATP/ADP biosensor kidney organoids | Early energy metabolism readout in 3D renal models | Organoid compatibility, transporter validation, injury monitoring |
| Cancer metabolism | Perceval and multi-biosensor panels | Tumor metabolic adaptation and chemotherapy response analysis | 2D/3D/in vivo model compatibility, multiplex metabolic profiling |
Our Advantages
- Integrated probe and biosensor development: We combine molecular probe design, genetically encoded biosensor workflows, photophysical characterization, biochemical testing, and biological validation to generate ATP/ADP detection systems that are sensitive, quantitative, and biologically meaningful.
- Mitochondria-focused energy metabolism expertise: Our platform supports ATP/ADP probe development for oxidative phosphorylation, respiratory chain dysfunction, metabolic reprogramming, mitochondrial toxicity, hypoxia, and energy stress models.
- Flexible detection strategy: We support fluorescence, ratiometric imaging, time-resolved luminescence, bioluminescence, enzymatic cycling, genetically encoded reporters, plate-reader assays, and high-content imaging formats.
- Application-oriented assay optimization: Probe performance can be tailored for live-cell imaging, organoid models, cancer metabolism, nephrotoxicity evaluation, drug discovery, mitochondrial-targeted compound screening, and translational metabolic research.
- Multi-parameter mitochondrial profiling: ATP/ADP analysis can be integrated with NADH/NAD⁺ ratio, ATP content, oxygen consumption, glycolysis, mitochondrial membrane potential, ROS, calcium, apoptosis, cell viability, and mitochondrial morphology assays to build a complete mitochondrial energy metabolism profile.
Contact Us
Develop sensitive, selective, and application-specific ATP/ADP probes with Protheragen's ATP/ADP Probes Development Service. Contact us with your target model, preferred detection platform, sample type, biosensor or small-molecule probe preference, throughput requirement, mitochondrial localization need, and research objective. Our team will recommend a tailored probe or assay development strategy for mitochondrial energy metabolism analysis, live-cell ATP/ADP imaging, drug screening, organoid toxicity evaluation, cancer metabolism research, and translational metabolic profiling.
Reference
1. Garde, A., & Sherwood, D. R. (2022). Visualizing cytoplasmic ATP in C. elegans larvae using PercevalHR. STAR protocols, 3(2), 101429.
